Skip to content
Search

Latest Stories

PDA to reach out to LloydsPharmacy for better pay hike as pharmacists reject 'unacceptable' offer

The Pharmacists' Defence Association (PDA) Union says it will be reaching out to LloydsPharmacy soon over a better deal on salary increase after the majority of its members rejected a three per cent offer made by the company recently.

Paul Day, director, PDA Union told Pharmacy Business: “The PDA Union will communicate the response of employed pharmacists to the company and seek further discussion to try and find an offer that will be acceptable to union members.


“Both management and union representatives have a vested interest in working to find such a solution and that is the outcome we hope to achieve.”

After months of negotiation by the PDA Union, the company offered a three per cent increase in salaries from the 1.8 per cent in the earlier offer made by the company.

“Through negotiation over last few months that was increased to 3.0 per cent, plus a long term incentive plan (LTIP).  Though the LTIP potentially offers large bonuses, it isn’t guaranteed. Therefore what we put to members was the confirmed offer of three per cent  increase in salaries,” said Paul.

However, the majority of the members voted to reject the offer.

Paul added: “We are going back to the company to see if a better deal can be reached.”

Since February, the Union is in talks with the company to secure an offer that is acceptable to its member. Lloyds Pharmacists had made offers to increase pay by 1.8 per cent and 2.3 per cent, the latter coupled with a Long Term Incentive Plan (LTIP) that will deliver further increases in income, but not for two years. But both the offers were earlier rejected by the members.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less